Clinical Trial Update: Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating AK104 in neoadjuvant/adjuvant therapy for microsatellite instability-high or mismatch repair-deficient resectable colon/colorectal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer with Msi-h Dmmr

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer | Phase 3 | Status: RECRUITING